anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Objective. This paper aims to investigate the possibility of detecting tonic-clonic seizures (TCSs) with behind-the-ear, two-channel wearable electroencephalography (EEG), and to evaluate its added value to non-EEG modalities in TCS detection.Methods. We included 27 participants with a total of 44 TCSs from the European multicenter study SeizeIT2. The wearable Sensor Dot (Byteflies) was used to measure behind-the-ear EEG, electromyography (EMG), electrocardiography, accelerometry (ACC) and gyroscope. We evaluated automatic unimodal detection of TCSs, using sensitivity, precision, false positive rate (FPR) and F1-score. Subsequently, we fused the different modalities and again assessed performance. Algorithm-labeled segments were then provided to two experts, who annotated true positive TCSs, and discarded false positives.Results. Wearable EEG outperformed the other single modalities with a sensitivity of 100% and a FPR of 10.3/24 h. The combination of wearable EEG and EMG proved most clinically useful, delivering a sensitivity of 97.7%, an FPR of 0.4/24 h, a precision of 43%, and an F1-score of 59.7%. The highest overall performance was achieved through the fusion of wearable EEG, EMG, and ACC, yielding a sensitivity of 90.9%, an FPR of 0.1/24 h, a precision of 75.5%, and an F1-score of 82.5%.Conclusions. In TCS detection with a wearable device, combining EEG with EMG, ACC or both resulted in a remarkable reduction of FPR, while retaining a high sensitivity.Significance. Adding wearable EEG could further improve TCS detection, relative to extracerebral-based systems.
Patients with suspected fungal neutropenia and fever will receive amphotericin B liposome 3 mg/kg intravenously. Treatment will be continued until the ANC≥500 /mm\^3 (0.5×10\^9 /L) for more than 72 hrs in terms of patients without evidence of baseline fungal infection and breakthrough fungal infection; or treatment will be continued according to investigator's judgement with a duration ranging from 14 days to 12 weeks in terms of patients with evidence of baseline fungal infection and breakthrough fungal infection.
The recommended dosage range for FETZIMA is 40 mg to 120 mg once daily, with or without food. FETZIMA should be initiated at 20 mg once daily for 2 days and then increased to 40 mg once daily. Based on clinical response and tolerability, FETZIMA may be increased in increments of 40 mg at intervals of 2 or more days. The maximum recommended dosage is 120 mg once daily.

Take FETZIMA at approximately the same time each day. Swallow FETZIMA whole; do not open, chew, or crush the capsule.
NEW MATERIAL:The monoclonal antibody bonding with apolipoprotein B48 in normal human blood, having lower bondability to apolipoprotein B100 than apolipoprotein B48, inert to other proteins in normal human blood, and capable of bonding with the lipoprotein in the blood of the patient of TG-normal-type abetalipoproteinemia. USE:Determination of lipoproteins causing arteriosclerosis, diagnosis of abetalipoproteinemia, etc. PREPARATION:For example, kairomicron is separated from the blood plasma of a normal person after the administration of a large amount of fat, and apolipoprotein B48 is separated from the kairomicron and purified. A mouse is immunized by the subcutaneous injection of the apolipoprotein B48 together with adjuvant. The spleen of the immunized mouse is extracted to collect the spleen cell, which is fused with myelocystoma using polyethylene glycol. The produced hybridoma is cloned e.g. by the critical dilution method to otain monoclonal antibody-producing hybridoma. The objective monoclonal antibody can be prepared by infusing the hybridoma into the abdominal cavity of mouse.
BACKGROUND: Incidence of anal squamous cell carcinoma is increasing, but vaccination against human papillomavirus (HPV) and removal of precancerous anal lesions could prevent new cases. The overall HPV-associated cancer incidence is reported to be higher in rural populations and in counties with lower economic status. We assessed these differences specifically for HPV-associated anal squamous cell carcinoma and described the geographic, county-level economic, and sociodemographic variations in incidence rates and trends.
METHODS: We analyzed data from the US Cancer Statistics to assess age-standardized incidence rates of HPV-associated squamous cell carcinomas among adults aged 18 years and older from 2001 to 2019. We calculated rate ratios and 95% confidence intervals to examine differences in incidence rates. We also quantified changes in incidence rates over time using joinpoint regression.
RESULTS: From 2001 to 2019, 72 421 new cases of HPV-associated anal squamous cell carcinoma were diagnosed among women (2.8 per 100 000) and 37 147 among men (1.7 per 100 000). Age-standardized incidence rates were higher in the South compared with other census regions and in counties ranked in the bottom 25% and 25%-75% economically than in the top 25%. The overall incidence rate increased in women but remained stable in men during 2009-2019. Incidence rates increased in adults aged 50 years and older but decreased among those aged 40-44 years from 2001 to 2019 in women and from 2007 to 2019 in men.
CONCLUSIONS: There were inequities in HPV-associated anal squamous cell carcinoma incidence by geographic and county-level economic characteristics. Failure to improve vaccine and treatment equity may widen existing disparities.
Idiopathic pulmonary fibrosis (IPF) is a progressive respiratory disease with no known cause. It is characterized by widespread inflammation and structural abnormalities in the alveoli of the lungs, ultimately leading to the development of pulmonary fibrosis. Triptolide (TP), an epoxy-diterpene lactone compound known for its potent anti-inflammatory and antifibrotic effects, was limited clinical use due to poor water solubility and side effects. Two soluble TP prodrugs (PG490-88 and Minnelide) have entered clinical research. However, their activities are based on enzyme metabolism, which is influenced by species-specific differences. In this study, we present water-soluble TP derivatives synthesized by introducing ethylenediamine carbamate groups (TP-DEAs) at the 14-hydroxy position. The introduced groups were found to spontaneously convert into the parent drug through enzyme-independent metabolic conversion. The water solubility and stability of the compounds were examined in vitro. Notably, TP-DEA2 exhibited high water solubility (30.8 mg/mL), exceeding TP solubility by more than 1181-fold. In vitro, TP-DEA2 converted to TP autonomously without the involvement of enzymes. In addition, TP-DEA2 can inhibit the expression of a disintegrin and metalloproteinase 10 (ADAM 10) induced by TGF-β1 and reduce the secretion of a-SMA in fibroblasts. In vivo, TP-DEA2 transformed into TP, effectively inhibiting fibrosis in the bleomycin group without observed toxicity. Importantly, positive outcomes when administering TP-DEA2 at a later stage post-bleomycin exposure suggest its potential role in treating IPF.
<P>PROBLEM TO BE SOLVED: To resolve problems in a conventional system wherein pieces of information of all recorded patients leak out when a code is broken since pieces of medical information of a plurality of people are collectively managed, and it can not correspond when the medical information is necessary quickly such as in an emergency.  <P>SOLUTION: The portable semiconductor recording medium 1 has a security controlled region 3. Enciphered medical information is enciphered again by an authentication number 5 and it is recorded in a medical information recording region 2. In reading, an authentication device 4 carries out an authentication process with the security controlled region 3 by an input of the authentication number 5 by the carrying person, and if collation is normal, the medical information is read by a reader-writer 6, and it is displayed in a display device 7. By this, the medical information recorded in the semiconductor recording medium 1 can not be read without an authentication procedure by the owner, and since it is doubly enciphered, a system with high safety and suiting carrying can be constructed.  <P>COPYRIGHT: (C)2003,JPO
Part A will comprise of 4 TPs. The subjects in this cohort will receive matching Placebo solution to the study drug GSK3358699 solution for 1 mg and a matching placebo capsule to the study drug GSK3358699, 10 mg and 35 mg capsule, during TP (1 to 3). Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 1 will receive Placebo at a dose level already given in TP 1-3, and will then receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram post administration of Placebo. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge. LPS dose will be based on data of study 207654 (NCT03306589).
They will be selected from healthy subjects who attend the restorative dental clinic and has clinically healthy gingiva with zero plaque index, gingival index and clinical attachment level \& probing depth ≤ 3 mm. Plaque samples will be collected.
Excessive dosage of calcium acetate induces hypercalcemia; therefore, early in the treatment during dosage adjustment serum calcium should be determined twice weekly. Should hypercalcemia develop, the dosage should be reduced or the treatment discontinued immediately depending on the severity of hypercalcemia. Calcium acetate should not be given to patients on digitalis, because hypercalcemia may precipitate cardiac arrhythmias. Calcium acetate therapy should always be started at low dose and should not be increased without careful monitoring of serum calcium. An estimate of daily calcium intake should be made initially and the intake adjusted as needed. Serum phosphorus should also be determined periodically.
<P>PROBLEM TO BE SOLVED: To provide a medicament-encapsulated micell with high stability of a medicament encapsulated therein and also enabling a large amount of the medicament to be encapsulated therein (i.e. high in encapsulation efficiency), and to provide a block copolymer for forming the micell.  <P>SOLUTION: The medicament-encapsulated micell is such that a hydrophobic region in a conventional medicament-encapsulated micell is made to be a hydrophobic liquid crystalline region. Thus, in encapsulating a medicament, the medicament is encapsulated at a temperature higher than the phase transition temperature between a liquid crystalline phase and a solid crystalline phase, leading to enabling a large amount of a medicament solution to be encapsulated as the hydrophobic liquid crystalline region constituting a micell inner core becomes a liquid phase. Whereas, by making micell temperature lower than the above phase transition temperature, the inner core becomes a solid crystalline phase, leading to discharging a solvent containing the encapsulated medicament to effect encapsulating the solid medicament, resulting in higher encapsulation stability of the medicament.  <P>COPYRIGHT: (C)2009,JPO&INPIT
COLD-MI study aims to explore colchicine's impact on myocardial denervation following reperfused acute myocardial infarction. Acute myocardial infarction is the leading cause of heart failure (HF). It induces myocardial denervation predisposing to ventricular rhythm disorders and death. This denervation linked to infarction's size occurs by direct ischaemic mechanisms during the initial coronary occlusion (initially non-vascularised zone) and secondarily by cardiac remodelling in the context of the heart failure (HF). In usual practice, cardiac denervation which intensity is correlated with rhythm and mortality risks, can be evaluated by scintigraphy. In a murine reperfusion model of ischemia, the direct anti-inflammatory effect of colchicine reduces the size of the necrosis and improves post-ischemic remodeling. This suggests that colchicine may reduce myocardial denervation.
The high prevalence of conversion from amnestic mild cognitive impairment (aMCI) to Alzheimer's disease (AD) makes early prevention of AD extremely critical. Neuroticism, a heritable personality trait associated with mental health, has been considered a risk factor for conversion from aMCI to AD. However, whether the neuroticism genetic risk could predict the conversion of aMCI and its underlying neural mechanisms is unclear. Neuroticism polygenic risk score (N-PRS) was calculated in 278 aMCI patients with qualified genomic and neuroimaging data from ADNI. After 1-year follow-up, N-PRS in patients of aMCI-converted group was significantly greater than those in aMCI-stable group. Logistic and Cox survival regression revealed that N-PRS could significantly predict the early-stage conversion risk from aMCI to AD. These results were well replicated in an internal dataset and an independent external dataset of 933 aMCI patients from the UK Biobank. One sample Mendelian randomization analyses confirmed a potentially causal association from higher N-PRS to lower inferior parietal surface area to higher conversion risk of aMCI patients. These analyses indicated that neuroticism genetic risk may increase the conversion risk from aMCI to AD by impairing the inferior parietal structure.
1,221,241. Detergent composition. CINCINNATI MILLING MACHINE CO. 1 Feb., 1968 [1 Feb., 1967; 9 Jan., 1968], No. 5275/68. Heading C5D. A detergent composition causing reduced skin irritation comprises a mildness additive of formula Y-R-Y<SP>1</SP> wherein R is a divalent organic radical containing a chain of at least 15 atoms between the open valences, a majority of which are carbons, and a cyclic group of at least 5 carbons, and is (A) a hydrocarbon radical, (B) an ester radical of a cyclic dicarboxylic acid and a polyol, or (C) an amide radical of a cyclic dicarboxylic acid and a polyamine, and wherein Y and Y<SP>1</SP> are polar groups containing carbon, nitrogen, oxygen, phosphorus, sulphur, or combinations thereof, said additive or its salt being liquid or soluble or colloidally dispersible in aqueous media, the polar groups of the mildness additive being stable and compatible with those of the detergent in aqueous media, the weight ratio of said additive to detergent being 0À005-10. R may be a C 15-80  hydrocarbon radical, and may be derived from the polymerized ethylenically unsaturated C 12-26  fatty acids. R may be a polyester radical derived by the reaction of a polyoxyalkylene glycol containing 1-30 oxyalkylene units, said alkylene groups having from 2-4 carbons with a dimer of a C 12-26  fatty acid, benzene dicarboxylic acid, a dihydrophthalic acid, a tetrahydrophthalic acid, or a cyclohexane dicarboxylic acid. R may alternatively be an amide radical derived by the reaction of a dimer of a C 12-26  fatty acid, benzene dicarboxylic acid, a dihydrophthalic acid, a tetrahydrophthalic acid, or a cyclohexane dicarboxylic acid with an alkanolamine containing 2-4 carbons. The degree of polymerization of polyester or polyamide is 1-10. The polar groups Y, Y<SP>1</SP> may be hydroxyl, carboxyl, carboxyl salt, amino, substituted amino, amido, substituted amido, ester, sulphate, sulphonate, phosphate, phosphonate, sulphate salt, sulphonate salt, phosphate salt, or quaternary ammonium salt groups. 10-80% by weight of the composition may consist of builders and other adjuvants.
Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W. Participants in Arm A have the option to cross over to combination treatment with autogene cevumeran plus pembrolizumab (Arm B) after confirmed disease progression.
Acute lung injury is a critical illness syndrome consisted of acute hypoxemic respiratory failure with bilateral pulmonary infiltrates that are not attributed to left atrial hypertension. The severity of the hypoxemia differentiates these two entities, with a ratio of partial pressure of oxygen in arterial blood (PaO2) to inspired fraction of oxygen (FIO2) of less than 200 mm Hg for ARDS and of less than 300 mm Hg for ALI.\[1\] Although ARDS initially was reported in 1967 by Ashbaugh and colleagues\[2\], it was not until 1992 that the American-European Consensus Conference (AECC) on ARDS developed a standardized definition for ARDS and ALI. There are many epidemiologic researches about the incidence and mortality of the ALI/ARDS.\[3-6\] Gorden D \[3\] reported that a total of 1113 King County residents undergoing mechanical ventilation met the criteria for acute lung injury and were 15 years of age or older. On the basis of this figure, the crude incidence of acute lung injury was 78.9 per 100,000 person-years and the age-adjusted incidence was 86.2 per 100,000 person-years. The in-hospital mortality rate was 38.5 percent. In our country, Yueming Lu \[7\] reported in-hospital and 90-day mortalities of ARDS patients were 68.5 and 70.4% in Shanghai ICU in 2004.

In recent years, significant progress has been made in the diagnosis and treatment of the ALI/ARDS, such as the application of the lung protective ventilation strategy and the CRRT, which may prove the symptoms and the prognosis of the ALI/ARDS. However, controversies still remained. Ventilation drive pressure, early application of neuromuscular blockade, strategy of PEEP level are frequently met questions in routine practice. In our country, a guideline for the treatment and diagnosis of ALI/ARDS was developed in 2006 \[8\]. So the incidence and the mortality of this disease are unknown in our country now. Therefore, the investigators will perform a prospective, multi-center study to survey the incidence, risk factors and outcome of ALI/ARDS in 13 adult ICU in Shanghai.
PURPOSE:To prepare a pharmaceutical adhesive plaster having suppressed decomposition of the drug component and improved stability, by compounding a polyphosphoric acid to a plaster base composed of an acrylic adhesive substance. CONSTITUTION:The objective plaster is obtained by compounding a plaster base composed of an acrylic adhesive substance (e.g. n-butyl methacrylate) with one or more polyphosphoric acids or its salts (e.g. dipolyphosphoric acid). The application of a drug component to the skin is carried out usually by the use of a pharmaceutical adhesive plaster obtained e.g. by compounding the drug component to a plaster composed of an adhesive substance. When a pharmaceutical preparation obtained by compounding a drug, especially a compound containing phenolic OH-group or an amine compound to a plaster composed of an acrylic adhesive substance is stored for a long period, the remedying effect is remarkably decreased by the decomposition and dissipation of the drug component. The decomposition of the drug can be suppressed by compounding polyphosphoric acid or its salt to the plaster. The amount of polyphosphoric acid added to the acrylic adhesive is about preferably 0.005-2wt%.
Atherosclerosis is a disease in blood vessels that often results in plaque formation and lumen narrowing. It is an inflammatory response of the tissue caused by disruptions in the vessel wall nourishment. Blood vessels are nourished by nutrients originating from the blood of the lumen. In medium-sized and larger vessels, nutrients are additionally provided from outside through a network of capillaries called vasa vasorum. It has recently been hypothesized (Haverich in Circulation 135:205-207, 2017) that the root of atherosclerotic diseases is the malfunction of the vasa vasorum. This, so-called outside-in theory, is supported by a recently developed numerical model (Soleimani et al. in Arch Comput Methods Eng 28:4263-4282, 2021) accounting for the inflammation initiation in the adventitial layer of the blood vessel. Building on the previous findings, this work proposes an extended material model for atherosclerosis formation that is based on the outside-in theory. Beside the description of growth kinematics and nutrient diffusion, the roles of monocytes, macrophages, foam cells, smooth muscle cells and collagen are accounted for in a nonlinear continuum mechanics framework. Cells are activated due to a lack of vessel wall nourishment and proliferate, migrate, differentiate and synthesize collagen, leading to the formation of a plaque. Numerical studies show that the onset of atherosclerosis can qualitatively be reproduced and back the new theory.
HAART eligibility screening entails presenting to the study site within 2 weeks of pre-screening, undergoing laboratory testing and providing a medical history, and returning for results within the subsequent four weeks. Any potential subjects who appear to be acutely intoxicated will be asked to return the next day or at a later date or time of their choosing. All participants will be asked to return for their results within four weeks after screening. Subjects will have 70 mL of whole blood collected by venipuncture by a trained study nurse. Laboratory tests will include HIV confirmatory testing (antibody and Western blot), CD4 cell count and plasma HIV-1-RNA level (plasma viral load; pVL), Hepatitis A, B and C serology, pregnancy test for women of child-bearing potential, complete blood count (CBC) with differential and platelet count, chemistry profile (creatinine, urea and electrolytes), and transaminase levels (ALT, AST). All participants will also have a medical history taken and undergo a physical examination. Recorded data will include subject gender, age, ethnicity, race, area of residence and living arrangement (categorized as homeless/on the street, unstable \[defined as living primarily in a single room occupancy hotel, boarding room, or transition house\] or stable). Additional features which will be recorded will include nature and frequency of illicit substance use, and participation in other cohort studies or methadone maintenance programs. All clinical past medical history and co-morbidities and laboratory data will be recorded for assessment of subject HAART eligibility.

All subjects who return for the results, whether HAART-eligible or not, will have their laboratory results explained to them and will be counseled as to a recommended course of clinical care by the study nurse. Those eligible for HAART will be offered enrollment into Part II of the study. Those not eligible for HAART will be invited to re-evaluate their eligibility for antiretroviral therapy at yearly intervals through the study site. Once 150 subjects have been randomized to each of the two study arms (total n=300), recruitment will be temporarily halted and statistical analysis will determine whether the reinforcer resulted in a significant and clinically relevant increase in the proportion of subjects who complete HAART eligibility screening.